Germany Archives

News and Trends 9 Nov 2017

Doctors Use Genetically Modified Stem Cells to Give a Boy New Skin

The ‘butterfly child’ who lost 80% of his skin has been successfully treated. The boy is now able to go to school and enjoy life with family and friends. A medical team from the Ruhr-Universität Bochum’s burn unit and the Center for Regenerative Medicine at the University of Modena have treated a boy suffering from […]

November 9, 2017 - 3 minutesmins - By Alex Dale

News and Trends 8 Nov 2017

German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration

Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […]

November 8, 2017 - 3 minutesmins - By Alex Dale

News and Trends 8 Nov 2017

German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development

InflaRx has announced that its shares will cost $15 when they’re launched for the company’s IPO, which could bring in over $100M for the biotech. InflaRx focuses on developing monoclonal antibodies targeted towards the complement system to treat potentially fatal inflammatory diseases. The company that its share will cost $15 (€13) when the company launches its IPO, […]

November 8, 2017 - 2 minutesmins - By Alex Dale

News and Trends 6 Nov 2017

German Biotech Teams Up with BioNTech to Boost Antibody Development

MAB Discovery and BioNTech are working together to push through the development of new antibody therapeutics using MAB’s technology platform. MAB Discovery creates monoclonal antibodies by stimulating natural antibody maturation using its own sophisticated platform. On the back of a highly productive agreement signed in 2013, BioNTech, Europe’s largest privately held biopharma, has moved to agree […]

November 6, 2017 - 1 minutemin - By Alex Dale

CureVac Moderna Therapeutics Biotech Unicorn Battle mRNA

Interview 6 Nov 2017

Battle of the Biotech Unicorns: CureVac vs. Moderna

An interview never seen before. We brought together the founders and CEOs of the two biotech unicorns pioneering mRNA therapy: CureVac in Germany and Moderna Therapeutics in the US. The idea of messenger RNA as a therapy is simple but brilliant: instead of giving a protein to a patient, you give their body the instructions […]

November 6, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2017

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical need. With the announcement of a €18M Series A, it hopes to take begin moving its candidates into the clinic. It had raised €14M thanks to investment from Epidarex […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 30 Oct 2017

German Pharmacist Finds a Way to Put the Brakes on Gallbladder Cancer

Research has identified a protein that drives tumor growth, which opens up a new therapeutic target for gallbladder cancer. Gallbladder cancer is often detected too late to be treated effectively as it shows few symptoms. Research, published in Oncotarget, has identified a pathway that could help to improve prognosis and treatment of the disease. Sonja Kessler discovered […]

October 30, 2017 - 3 minutesmins - By Alex Dale

In Depth 24 Oct 2017

Where to Find the Money to Get Your Biotech Startup Up with the Big Boys

What do you need to kickstart your own biotech company? A great idea, of course. Industry knowledge, a plus. Money… This could be tricky. Breaking into the biotech industry is one of the most expensive decisions that you can make. First, you need ground-breaking science that has what it takes to change its respective field, […]

October 24, 2017 - 8 minutesmins - By Alex Dale

Interview 23 Oct 2017

The German CEO Pushing for an Immunotherapy to Treat Cancer and HIV

Mariola Söhngen, CEO of Mologen, discusses biotech entrepreneurship in Germany and her company’s unique immunotherapy against both cancer and HIV. Mariola Söhngen has an outstanding track record as an entrepreneur and leader in biotech and pharma. In 1998, after 10 years working with big pharma, she founded her first company, Bootcamp, to help young professionals […]

October 23, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2017

Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines

CureVac will be working with pharma giant Eli Lilly in the development of up to five cancer vaccines based on mRNA technology. Eli Lilly will pay CureVac $50M (€43M) upfront and invest €45M in equity to kick off a collaboration for the development and commercialization of up to five mRNA vaccines for cancer. CureVac could receive up […]

October 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2017

German Researchers Set the Immune System Free to Fight Against Cancer

There could be a way to stop cancers escaping from the immune system, and researchers hope to use this for more effective cancer treatments. Researchers at Universität Bonn have found a way to “release the brakes” in the immune system that helps cancers to survive. Cancers benefit from this by pretending to be regular cells, […]

October 18, 2017 - 2 minutesmins - By Alex Dale

News and Trends 16 Oct 2017

German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb

Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting ready to start two Phase II trials to study the safety and efficacy of its candidate PQ912, a drug designed to intervene in the early stages of […]

October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us